Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (8592)	2/3/1999 2:13:00 AM
From: aknahow	Respond to of 17367

opala, I still like XOMA a lot. I think they do one of the better jobs in the I.R. area. What don't I like? Well lets say you ask them if the trial is over. They would probably say no. but would you know what the no means? Suppose accruals were halted and you asked if the trial was over. XOMA would still probably say no. Technically they would be correct in that the trial does not end until it is totally unblinded. But I think shareholders merit knowing when accruals are complete. Then as mortality is unblinded, I think we all, merit knowing at the same time what the data showed. I do not buy and resent that some in XOMA might consider that the scientific community must get this information first. We have all taken enough risk without having to put up with data being available to others first, so they can act on it at their leisure.